![Peter Sondermann](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter Sondermann
Chief Executive Officer at TACALYX GmbH
Peter Sondermann active positions
Companies | Position | Start | End |
---|---|---|---|
TACALYX GmbH
![]() TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Chief Executive Officer | - | - |
Founder | - | - |
Career history of Peter Sondermann
Former positions of Peter Sondermann
Companies | Position | Start | End |
---|---|---|---|
SuppreMol GmbH
![]() SuppreMol GmbH Pharmaceuticals: MajorHealth Technology SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany. | Chief Tech/Sci/R&D Officer | 01/01/2002 | - |
Founder | 01/01/2002 | - | |
Max Planck Institute of Biochemistry | Corporate Officer/Principal | - | - |
Roche Glycart AG
![]() Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Corporate Officer/Principal | 26/11/2009 | - |
Training of Peter Sondermann
University of Bielefeld | Doctorate Degree |
Statistics
International
Germany | 5 |
Switzerland | 2 |
Operational
Corporate Officer/Principal | 2 |
Founder | 2 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 3 |
---|---|
Roche Glycart AG
![]() Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Health Technology |
SuppreMol GmbH
![]() SuppreMol GmbH Pharmaceuticals: MajorHealth Technology SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany. | Health Technology |
TACALYX GmbH
![]() TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Commercial Services |
- Stock Market
- Insiders
- Peter Sondermann
- Experience